Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208476 | 0.89 | KAT6A (0.49) | KAT6APARP10PARP15SIRT2TLR4 | |
| SCHEMBL2208472 | 0.89 | KAT6A (0.49) | KAT6APARP10PARP15SIRT2TLR4 | |
| SCHEMBL4569102 | 0.89 | KAT6A (0.49) | KAT6APARP10PARP15SIRT2TLR4 | |
| SCHEMBL18550944 | 0.87 | KAT6A (0.45) | KAT6APARP10PARP15SIRT2TLR4 | |
| SCHEMBL25823093 | 0.85 | KAT6A (0.43) | KAT6APARP10PARP15SIRT2TLR4 | |
| SCHEMBL2207567 | 0.82 | KAT6A (0.49) | KAT6APARP10PARP15SIRT2TLR4 | |
| SCHEMBL25826152 | 0.82 | SIRT2 (0.44) | KAT6APARP10PARP15SIRT2TLR4 | |
| SCHEMBL17031422 | 0.82 | KAT6A (0.45) | KAT6APARP10PARP15SIRT2TLR4 | |
| SCHEMBL4568815 | 0.82 | KAT6A (0.45) | KAT6APARP10PARP15SIRT2TLR4 | |
| SCHEMBL19291604 | 0.81 | KAT6A (0.47) | KAT6APARP10PARP15SIRT2TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | KAT6A 1820/4885PARP10 1814/4885PARP15 2520/4885 |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KAT6A 1820/4885PARP10 1814/4885PARP15 2520/4885 |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KAT6A 1820/4885PARP10 1814/4885PARP15 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.